Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A recent Yahoo Finance comparison framed AbbVie as the lower-multiple option, while highlighting concentration risk and pointing to Johnson & Johnson’s broader healthcare footprint and balance-sheet strength as the main offset.
THE APEX TIMES
THE APEX TIMES
OmniAb, Inc. said it has entered a global collaboration and licensing agreement with Eli Lilly to discover and develop new ion channel therapeutics, a strategy that could validate OmniAb’s technology even as key financial and scientific details remain undisclosed.
THE APEX TIMES
A drop in employer insurance coverage for GLP-1 weight-loss drugs is emerging as a new constraint, even as Eli Lilly reports a steep jump in revenue linked to its obesity medicines.
THE APEX TIMES
The companies announced U.S. regulatory approval for an additional version of their jointly developed mRNA COVID-19 vaccine, underscoring the continuing cycle of variant updates.
THE APEX TIMES
The rating agency said it reaffirmed UnitedHealth Group’s long-term issuer credit rating and related long- and short-term issue credit ratings for the company and its subsidiaries.
THE APEX TIMES
A Yahoo Finance wrap-up of second-quarter results put Moderna’s performance in context with other healthcare therapeutics stocks, underscoring how investors weigh growth, pipeline progress, and near-term fundamentals.
THE APEX TIMES
The agency has cleared Mounjaro for a new indication aimed at lowering the risk of major cardiovascular events among adults with Type 2 diabetes who are considered at higher risk for heart attack or stroke.
THE APEX TIMES
A recent Yahoo Finance report highlighted CNBC host Jim Cramer’s recurring bullish view of Johnson & Johnson, pointing to what he framed as a stronger balance sheet than the government’s.
THE APEX TIMES
A regulatory step in China for Novo’s obesity medicine supports the possibility of a future launch, yet it does not resolve timing risks or guarantee approval. Eli Lilly still has a prominent position as the battle over GLP-1 oral therapy extends.
